Home Alzheimer’s Disease Use of Post-HSCT Cyclophosphamide Improves Transplantation Outcomes for AML/MDS

Use of Post-HSCT Cyclophosphamide Improves Transplantation Outcomes for AML/MDS

A study, published in Cancers, indicated that hematopoietic stem cell transplantation (HSCT) with prior use of checkpoint inhibitors appears feasible in patients with acute myeloid leukemia (AML) and/or myelodysplastic syndromes (MDS) and the use of post-HSCT cyclophosphamide (PTCy) as graft-versus host disease (GVHD) prophylaxis improves outcomes.

“Taken together, these data indicate that the use of prior checkpoint inhibitors needs to be considered within the donor/hematopoietic stem cell selection and GVHD prophylaxis plan for patients undergoing HSCT,” the authors wrote.

In this study, a retrospective analysis of 43 patients with AML and/or MDS who were treated with an antiprogrammed cell death protein 1 (PD-1) (32 patients) or anticytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (9 patients) blockade or both (2 patients) prior to HSCT with the primary outcome of acute…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments